NeuroSense Therapeutics Ltd. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
NRSN Nasdaq 2834 www.neurosense-tx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for NeuroSense Therapeutics Ltd.

NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada - Aug 6th, 2026 9:29 am
NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS - Jul 22nd, 2026 6:30 am
NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS" - Jul 6th, 2026 6:45 am
NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS - Jun 29th, 2026 7:30 am
NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease - Jun 25th, 2026 7:20 am
EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots - Jun 22nd, 2026 7:00 am
NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS - Jun 11th, 2026 7:00 am
NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition - Jun 9th, 2026 7:00 am
NeuroSense Announces Pricing of Insider-Led PIPE Financing - Apr 28th, 2026 12:30 pm
NeuroSense Granted Brazilian Patent Covering PrimeC Composition - Apr 6th, 2026 7:20 am
NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements - Apr 3rd, 2026 8:02 am
NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update - Mar 31st, 2026 7:20 am
NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout - Mar 24th, 2026 7:00 am
/C O R R E C T I O N -- NeuroSense/ - Mar 18th, 2026 8:44 am
JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity - Mar 16th, 2026 9:30 am
PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference - Mar 9th, 2026 9:07 am
NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS - Feb 18th, 2026 7:05 am
NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition - Feb 9th, 2026 7:20 am
NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease - Jan 21st, 2026 6:30 am
World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB - Jan 8th, 2026 6:45 am